Grab 20% Off With Code ONLINE20 On Global market Reports – Evaluate Global Trends, Market Risks, and Competitive Intelligence
What Is the Predicted Market Size and CAGR of the Low Endotoxin Gelatin Market by the End of the 2029?
The low endotoxin gelatin market size has grown strongly in recent years. It will grow from $1.72 billion in 2024 to $1.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historic period can be attributed to rising demand for biocompatible materials in pharmaceuticals, increasing use in vaccine and biologics manufacturing, growing concerns over endotoxin contamination, expansion of gelatin purification processes, and growing regulatory focus on injectable-grade excipients.
The low endotoxin gelatin market size is expected to see strong growth in the next few years. It will grow to $2.38 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to growing biopharmaceutical research and development investment, rising adoption of regenerative medicine and tissue engineering, increasing demand for cell culture and 3D bioprinting applications, stricter quality standards for parenteral products, and growing preference for animal-origin-free gelatin. Major trends in the forecast period include the development of recombinant and plant-based low-endotoxin gelatin, integration in advanced drug delivery systems, adoption of personalized medicine formulations, rising research and development activities, and automation in endotoxin testing and quality control.
Get your free report sample today:
What Are the Significant Market Forces Driving the Low Endotoxin Gelatin Market Performance?
The growing demand for regenerative medicine is expected to propel the growth of the low endotoxin gelatin market going forward. Regenerative medicine refers to therapies that repair, replace, or regenerate human cells, tissues, or organs to restore normal function. This regenerative medicine demand is increasing due to rising chronic diseases, as more patients require advanced therapies that can regenerate damaged tissues and improve long-term outcomes. Low-endotoxin gelatin aids regenerative medicine by offering a safe, biocompatible scaffold that promotes cell growth and tissue regeneration with minimal immune reaction. Its high purity makes it ideal for sensitive cell therapies and tissue engineering. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, at the end of quarter 1, 2023, there were 247 gene therapies in Phase II. This figure increased by 5%, reaching 260 by the end of quarter 2. Therefore, the growing demand for regenerative medicine is driving the growth of the low endotoxin gelatin market.
Which Segments Are Likely to Shape the Future Outlook of the Low Endotoxin Gelatin Market?
The low endotoxin gelatin market covered in this report is segmented –
1) By Type: Type A (Acid Process Gelatin), Type B (Alkaline Process Gelatin)
2) By Product Type: Porcine Gelatin, Bovine Gelatin, Fish Gelatin, Other Product Types
3) By Formulation: Powder, Granules, Liquid, Sheet, Other Formulations
4) By Application: Drug Delivery Systems, Tissue Engineering, Cell Culture, Stabilizing Agents, Thickening Agents
5) By End-User: Pharmaceuticals, Biotechnology, Food And Beverage, Cosmetics, Research Laboratories
Subsegments:
1) By Type A (Acid Process Gelatin): Porcine Skin Gelatin, Fast Setting Gelatin, Low Bloom Gelatin, Pharmaceutical Grade Type A, Biotech Application Grade
2) By Type B (Alkaline Process Gelatin): Bovine Hide Gelatin, High Bloom Gelatin, Slow Dissolving Gelatin, Injectable Grade Type B, Regenerative Medicine Grade
What Are the Key Industry Trends Driving Growth in the Low Endotoxin Gelatin Market?
Major companies operating in the low endotoxin gelatin market are focusing on developing advanced products such as endotoxin-controlled excipients to enhance the safety and efficacy of pharmaceutical formulations. Endotoxin-controlled excipients are highly refined ingredients designed to limit endotoxin presence in pharmaceutical formulations. They support the safety and reliability of sensitive products such as injectables, biologics, and cell-based therapies. For instance, in January 2025, GELITA, a Germany-based manufacturer of gelatin and collagen peptides, launched VACCIPRO and MEDELLAPRO. These excipients are highly purified, medical-grade gelatins and collagen peptides designed for advanced bioscience applications such as vaccine stabilization, medical devices, and 3D bioprinting, meeting stringent endotoxin control requirements to ensure product safety and patient well-being in pharmaceutical and healthcare settings.
Which Major Organizations Influence the Direction of the Low Endotoxin Gelatin Market?
Major companies operating in the low endotoxin gelatin market are Nagase & Co. Ltd., Darling Ingredients, GELITA AG, PB Leiner, Nippi Inc., Nitta Gelatin Inc., Weishardt Group, Sterling Biotech Limited, Narmada Gelatines Ltd., Great Lakes Gelatin Company, Kenney & Ross Limited, Junca Gelatines SL, Trobas Gelatine BV, Lapi Gelatine S.p.a., Ewald-Gelatine GmbH, Niksan Pharmaceutical, Geltech, India Gelatine & Chemicals Ltd., Reinert Gruppe Ingredients GmbH, Jilin Tianzheng Biotechnology Co. Ltd., Yasin gelatin.
Get the detailed low endotoxin gelatin market report today
Which Region Holds the Largest Share of the Low Endotoxin Gelatin Market?
North America was the largest region in the low endotoxin gelatin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the low endotoxin gelatin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment